Browse

S-Space

Browsing by Author Park, Yeon Hee

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 46 of 46

Issue Date Title / Author(s) / CitationFileAltmetrics
2005-08
Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): Phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor
DOI
2005-12
Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I-E/IIE extranodal NK/T-cell lymphoma, nasal type
DOI
2006-02
Prognostic value of immunohistochemical staining of p53, bcl-2, and Ki-67 in small cell lung cancer
view file
2007-05
Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer
DOI
2008-03
Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer
DOI
2008-04
High prevalence of hepatitis B virus infection in patients with B-cell non-Hodgkin's lymphoma in Korea
DOI
2012-05
Small node-negative (T1b-cN0) invasive hormone receptor-positive breast cancers: Is there a subpopulation that might have benefit from adjuvant chemotherapy?
DOI
2013-05
Phase III, Multicenter, Randomized Trial of Maintenance Chemotherapy Versus Observation in Patients With Metastatic Breast Cancer After Achieving Disease Control With Six Cycles of Gemcitabine Plus Paclitaxel As First-Line Chemotherapy: KCSG-BR07-02
DOI
2014-03
Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy
DOI
2014-07
Validation and Comparison of CS-IHC4 Scores with a Nomogram to Predict Recurrence in Hormone Receptor-Positive Breast Cancers
DOI
2015-07
Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02)
DOI
2017-04
Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results
DOI
2017-11
Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
DOI
2018-11
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study)
DOI
2018-12
A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial
DOI
2019-01
Randomized Open Labe Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)
DOI
2019-05
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
view fileDOI
2019-09
Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients
DOI
2019-10
Treating HR+/HER2-breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression
DOI
2019-11
Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11)
DOI
2019-12
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): A multicentre, open-label, randomised, phase 2 trial
DOI
2019-12
Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2+metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
DOI
2020-02
Survival outcomes of breast cancer patients with brain metastases: A multicenter retrospective study in Korea (KROG 16-12)
DOI
2020-02
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
DOI
2020-09
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
DOI
2020-11
Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10)
DOI
2020-12
Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis
DOI
2020-12
Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib
DOI
2021-04
New brain metastases after whole-brain radiotherapy of initial brain metastases in breast cancer patients: the significance of molecular subtypes (KROG 16-12)
DOI
2021-07
Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis

Gelmon, Karen A.; Fasching, Peter A.; Couch, Fergus J.; Balmaña, Judith; Delaloge, Suzette; Labidi-Galy, Intidhar; Bennett, James; McCutcheon, Susan; Walker, Graham; O'Shaughnessy, Joyce; Collaborating Investigator; Timcheva, Constanta; Tomova, Antoaneta; Eisen, Andrea; Lemieux, Julie; Bazan, Fernando; Bourgeois, Hugues; Chakiba, Camille; Chehimi, Mohamad; Dalenc, Florence; De La Motte Rouge, Thibault; Frenel, Jean-Sébastien; Gonçalves, Anthony; Hardy-Bessard, Anne Claire; Lamy, Regine; Levy, Christelle; Lortholary, Alain; Mailliez, Audrey; Medioni, Jacques; Patsouris, Anne; Spaeth, Dominique; Teixeira, Luis; Tennevet, Isabelle; Villanueva, Cristian; You, Benoit; Ettl, Johannes; Gerber, Bernd; Hoffmann, Oliver; Park-Simon, Tjoung-Won; Reinisch, Mattea; Tio, Joke; Wimberger, Pauline; Boer, Katalin; Ballestrero, Alberto; Bianchini, Giampaolo; Biganzoli, Laura; Bordonaro, Roberto; Cognetti, Francesco; De Laurentiis, Michelino; De Placido, Sabino; Guarneri, Valentina; Montemurro, Filippo; Naso, Giuseppe; Santoro, Armando; Zamagni, Claudio; Kim, Seung-Jin; Nakamura, Seigo; Chae, Yee Soo; Cho, Eun Kyung; Hyun, Kim Jee; Im, Seock-Ah; Lee, Keun Seok; Park, Yeon Hee; Sohn, Joo Hyuk; Byrski, Tomasz; Huzarski, Tomasz; Kukielka-Budny, Bozena; Nowecki, Zbigniew; Szoszkiewicz, Renata; Tarnawski, Rafal; Dvornichenko, Viktoria; Moiseenko, Fedor; Mukhametshina, Guzel; Poddubskaya, Elena; Popova, Ekaterina; Tarasova, Anna; Vats, Anna; Adamo, Bárbara; Conejero, Raquel Andrés; Torres, Antonio Antón; Gelpi, Judith Balmaña; Fernández, Nieves Díaz; González, Alejandro Falcón; Garcia, Juan; Lorenzo-Lorenzo, Isabel; Antón, Fernando Moreno; Santisteban, Marta; Stradella, Agostina; Huang, Chiun-Sheng; Aksoy, Sercan; Arslan, Cagatay; Artac, Mehmet; Aydiner, Adnan; Ozyilkan, Ozgur; Sezer, Emel; Armstrong, Anne; Barrett, Sophie; Borley, Annabel; Kemp, Zoe; Michie, Caroline; Mukesh, Mukesh; Perren, Timothy; Swampillai, Angela; Young, Tammy

European Journal of Cancer, Vol.152, pp.68-77

DOI
2021-07
Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL)
DOI
2021-12
Novel prognostic classification predicts overall survival of patients receiving salvage whole-brain radiotherapy for recurrent brain metastasis from breast cancer: A recursive partitioning analysis (KROG 16-12)
DOI
2022-04
Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer
DOI
2022-07
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
DOI
2022-09
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial
DOI
2022-10
The Pattern of Care for Brain Metastasis from Breast Cancer Over the Past 10 Years in Korea: A Multicenter Retrospective Study (KROG 16-12)
DOI
2022-12
The impact of race and ethnicity in breast cancer-disparities and implications for precision oncology
DOI
2022-12
HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis
DOI
2023-04
A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)
DOI
2023-05
Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1)
DOI
2023-06
A Survey of Practice Patterns for Clinical Nodal Staging Prior to Neoadjuvant Chemotherapy in Breast Cancer
DOI
2023-07
Comparison of initial and sequential salvage brain-directed treatment in patients with 1-4 vs. 5-10 brain metastases from breast cancer (KROG 16-12)
DOI
2023-07
Eflapegrastim versus Pegfilgrastim for Chemotherapy-Induced Neutropenia in Korean and Asian Patients with Early Breast Cancer: Results from the Two Phase III ADVANCE and RECOVER Studies
DOI
2023-07
Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer
DOI
2023-07
Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer
view fileDOI
2023-12
Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16)
DOI
1

Seoul National University Library, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea TEL: 02-880-5567 Email: s-space@snu.ac.kr youtube

RSS 1.0 RSS 2.0 Atom

Hello

Browse

News About S-Space Seoul National University Library LOGIN